title: Chemotherapy of adult soft tissue sarcoma with combination of doxorubicin and methotrexate.
abstract: Thirty-six adult patients with measurable advanced soft tissue sarcoma were treated with a combination of doxorubicin (70 mg/m2) and methotrexate (50 mg/m2) iv every 21 days. Partial remission was seen in ten of 33 evaluable patients (30%). Median duration of remission was 23 weeks, and median survival was 42 weeks. Bone marrow toxicity was the main toxic effect; 23% of the patients had a nadir leukocyte count less than 2.0 X 10(9)/L during therapy. These results do not suggest any therapeutic advantage in adding methotrexate to doxorubicin in this context.
authors: Department of Clinical Oncology, Royal North Shore Hospital, St. Leonards, Sydney, New South Wales, Australia.
authors: P
authors: P
authors: Presgrave
authors: R L
authors: RL
authors: Woods
authors: M H
authors: MH
authors: Tattersall
authors: A S
authors: AS
authors: Coates
authors: J A
authors: JA
authors: Levi
authors: R M
authors: RM
authors: Fox
authors: D
authors: D
authors: Hedley
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*; D012509:Sarcoma / Q000188:drug therapy*
chemical_list: D004317:Doxorubicin; D008727:Methotrexate